MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 25.04.2026
Cellectis S.A. Betriebsaufwand 2011-2026 | CLLS
Betriebsaufwand Jährlich Cellectis S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 109 M | 106 M | 115 M | 142 M | 102 M | 147 M | 127 M | 126 M | 105 M | 82.9 M | 29 M | 67.1 M | 51.9 M | 42.8 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 147 M | 29 M | 96.6 M |
Betriebsaufwand Vierteljährlich Cellectis S.A.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 52.1 M | - | - | - | 37.6 M | - | - | - | 38.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 52.1 M | 37.6 M | 42.6 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.89 | - | $ 6.54 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.2 | - | $ 3.68 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Edesa Biotech
EDSA
|
6.71 M | $ 15.9 | - | $ 50.8 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Evogene Ltd.
EVGN
|
13.8 M | $ 0.76 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
598 M | $ 44.69 | - | $ 12.1 B | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Galapagos NV
GLPG
|
709 M | $ 27.86 | - | $ 2.69 B |  Belgium |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 7.91 | - | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
462 M | $ 31.05 | - | $ 1.79 B | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
9.8 M | $ 8.44 | - | $ 76.2 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 101.57 | - | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Incyte Corporation
INCY
|
1.62 B | $ 99.1 | - | $ 19.3 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
InMed Pharmaceuticals
INM
|
9.78 M | $ 0.7 | - | $ 1.71 M | Canada |
 |
INmune Bio
INMB
|
47.4 M | $ 1.33 | - | $ 32.9 M | USA |
 |
Innoviva
INVA
|
144 M | $ 23.05 | - | $ 1.55 B | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
63 M | $ 1.48 | -0.67 % | $ 235 M | France |
 |
Jaguar Health
JAGX
|
36 M | $ 7.88 | - | $ 18.4 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
161 M | $ 26.67 | - | $ 1.44 B | Britain |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Kamada Ltd.
KMDA
|
69 K | $ 8.11 | - | $ 260 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.98 | - | $ 4.91 M | Israel |
 |
Krystal Biotech
KRYS
|
228 M | $ 259.95 | - | $ 7.52 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
8.82 M | $ 12.42 | - | $ 1.65 B |  Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
115 M | $ 224.86 | - | $ 4.11 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Liquidia Corporation
LQDA
|
59.6 | $ 38.15 | - | $ 3.28 B | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.05 | - | $ 433 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |